Product How it works Pricing Blog FAQ About Contact
Kura Oncology

Kura Oncology (NASDAQ: KURA) revenue

Kura Oncology reported revenue of $67.5m for fiscal 2025, 25.2% more than in fiscal 2024 ($53.9m).

Fiscal 2025 is the highest of the 3 fiscal years on record for Kura Oncology.

Revenue, in millions of US dollars0.0202353.9202467.52025
Embed this chart

Copy this code into your website or blog. The chart updates with each new annual report.

Revenue by fiscal year

Fiscal yearRevenueChangeOperating profitOperating margin
2025$67.5m+25.2%−$303.6m−449.9%
2024$53.9m—−$193.2m−358.5%
2023$0.0m—−$165.8m—

The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.

Kura Oncology revenue compared with its sector

By revenue for its latest fiscal year, Kura Oncology ranks 317th of the 422 US health care companies with a page on Celsmar. The sector median grew 11.7% in its latest fiscal year; Kura Oncology, 25.2%.

RankCompanyRevenueRevenue growth
315thVir Biotechnology$68.6m−7.6%
316thIntellia Therapeutics$67.7m16.9%
317thKura Oncology$67.5m25.2%
318thEnanta Pharmaceuticals$65.3m−3.4%
319thNuvation Bio$62.9m699.0%

Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.

Questions about the revenue of Kura Oncology

How much revenue did Kura Oncology make in fiscal 2025?
Kura Oncology reported revenue of $67.5m for fiscal 2025, compared with $53.9m in fiscal 2024.
What was the best year for revenue at Kura Oncology?
Of its last 3 fiscal years, fiscal 2025, with $67.5m.
Where does Kura Oncology rank in its sector by revenue?
It ranks 317th of the 422 US health care companies with a page on Celsmar, by revenue for its latest fiscal year.
Where do the figures for Kura Oncology come from?
From the annual report (Form 10-K) that Kura Oncology files with the SEC, the US securities regulator. Each fiscal year links to its filing.

Where each figure comes from

From the annual report (Form 10-K) that Kura Oncology files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023. More on Kura Oncology: the Kura Oncology page · annual accounts · net income · insider transactions.

Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.